ZYXI 8x annualized PE with strong sequential quarterly growth. 35% sequential growth and 88% year over year growth. They plan to uplist. If the blood monitoring device gets approved that could be way bigger than their current product. They just moved into their new headquarters which is much bigger and can support revenue multiple times higher than it is now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.